Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:oxymorphone
|
| gptkbp:ATCCode |
gptkb:N02AA07
|
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:drugClass |
opioid
|
| gptkbp:form |
extended-release tablet
immediate-release tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Opana
|
| gptkbp:legalStatus |
prescription only (prior to withdrawal)
|
| gptkbp:manufacturer |
gptkb:Endo_Pharmaceuticals
|
| gptkbp:regulates |
withdrawn
|
| gptkbp:retired |
public health risks, abuse potential
|
| gptkbp:riskFactor |
addiction
overdose hepatitis C (from injection misuse) thrombotic microangiopathy (from injection misuse) |
| gptkbp:routeOfAdministration |
oral
intramuscular subcutaneous rectal |
| gptkbp:sideEffect |
nausea
constipation drowsiness respiratory depression |
| gptkbp:usedFor |
pain management
|
| gptkbp:withdrawn |
2017
|
| gptkbp:bfsParent |
gptkb:oxymorphone
|
| gptkbp:bfsLayer |
7
|